204005-46-9

基本信息
3-二氢-3-[(3
SU 5416, 一种VEGFR2/FLK1抑制剂
5-二甲基-1H-吡咯-2-基)亚甲基)吲哚啉-2-酮
5-二甲基-1H-吡咯-2-基)亚甲基]-2H-吲哚-2-酮
(Z)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)吲哚啉-2-酮
3-二氢-3-[(3,5-二甲基-1H-吡咯-2-基)亚甲基]-2H-吲哚-2-酮
1,3-二氢-3-[(3,5-二甲基-1H-吡咯-2-基)亚甲基]-2H-吲哚-2-酮
SU54161
SeMaxinib
(Z)-3-((3
Sugen 5416
SU5416 /SU-5416
SU 5416 semaxanib
SEMAXINIB(SU 5416)
SU 5416 (SeMaxinib)
SEMAXINIB
SU-5416
SU 5416
物理化学性质
熔点 | 226-228 °C |
沸点 | 481.4±45.0 °C(Predicted) |
密度 | 1.256±0.06 g/cm3(Predicted) |
储存条件 | -20°C |
溶解度 | H2O: insoluble |
溶解度 | 不溶于水 |
酸度系数(pKa) | 12.59±0.20(Predicted) |
形态 | 黄橙色固体 |
颜色 | yellow to yellow orange |
安全数据
危险性符号(GHS) | ![]() GHS07 |
警示词 | 警告 |
危险性描述 | H335-H319-H315 |
防范说明 | P264-P280-P302+P352-P321-P332+P313-P362-P264-P280-P305+P351+P338-P337+P313P |
危险品标志 | Xi |
危险类别码 | 36/37/38 |
安全说明 | 26-36 |
WGK Germany | 3 |
WGK Germany | 3 |
海关编码 | 29339900 |
SU5416价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-10374 | Semaxinib | 204005-46-9 | 5 mg | 612元 |
2025/02/08 | HY-10374 | SU5416 Semaxinib | 204005-46-9 | 10mM * 1mLin DMSO | 673元 |
2025/02/08 | HY-10374 | SU5416 Semaxinib | 204005-46-9 | 10mg | 980元 |
常见问题列表
Flk-1 1.23 μM (IC 50 ) |
Semaxinib (SU5416) inhibits VEGF-driven mitogenesis in a dose-dependent manner with an IC 50 of 0.04±0.02 μM (n=3). In contrast, Semaxinib (SU5416) blocks FGF-dependent mitogenesis of HUVECs with an IC 50 of 50 μM (n=10). An IC 50 of 20.26±5.2 μM, which is about 20-fold less in potency on PDGF-dependent autophosphorylation, is observed when SU5416 is tested in NIH 3T3 cells overexpressing the human PDGF receptor β.
Daily administration of Semaxinib (SU5416) (i.p., 3 mg/kg/day) inhibits the local growth of C6 tumors in the colon. A comparable level of growth inhibition (62% by day 16; P=0.001) is observed for tumors growing in the colon in comparison with ones growing in the hindflank region (54% by day 18; P=0.001). These results indicate that Semaxinib (SU5416) could inhibit tumor growth at a site other than the subcutaneous implantation site, where the preexisting vasculature may be different. Daily treatment with Semaxinib (SU5416) (25 mg/kg) results in a significantly lower tumor growth rate with tumor masses of up to 8% of that present in control animals by day 22 after implantation. Inhibition of tumor growth is clearly preceded by a marked reduction of the tissue area covered by the newly formed glioma microvasculature in the Semaxinib-treated group, indicating a reduced initial tumor vascularization.